ArticleCureus2026
Vitiligo-Like Depigmentation in Nivolumab-Treated Nodular Melanoma: A Paradoxical Clinical Course.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Vitiligo-like depigmentation (VLD) is a recognized cutaneous adverse event associated with anti-programmed cell death protein-1 (anti-PD-1) therapy in patients with melanoma and has been linked to favorable therapeutic response and improved survival outcomes. We present the case of a 72-year-old woman diagnosed with metastatic nodular melanoma treated with nivolumab monotherapy, who developed disseminated VLD after multiple treatment cycles. Despite achieving an initial complete radiologic response and developing extensive depigmentation, the patient subsequently experienced disease progression, presenting hepatic, pulmonary, and central nervous system metastases. This case contrasts with the commonly reported association between VLD and favorable prognosis, emphasizing that this phenomenon may not consistently predict sustained clinical benefit in patients receiving immunotherapy for advanced melanoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.